PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Part of paid clinical trials in Aurora, Colorado.

Sponsor: University of Massachusetts, Worcester
Study ID: NCT06855329
Status: Recruiting

Conditions

Interstitial Lung Disease
Progressive Pulmonary Fibrosis

Eligibility Criteria

Sex: ALL
Age: 18 Years - 80 Years
Healthy Volunteers: Not accepted

Study Details

This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.

Key Dates

First listed: Mar 3, 2025
Start date: May 1, 2025
Status verified: Aug 2026
Primary completion: Dec 31, 2029
Completion: Dec 31, 2029

Study Design

Enrollment: 500 participants (estimated)

Primary Outcome Measure

Transplant-free survival (TFS) [ Time Frame: 12-months to 24-months (following an observation period from 0 months to 12 months) ]

Central Contacts

Fernando J Martinez, MD, MS
508-334-8685
[email protected]
Elizabeth Peters, BSN
774-455-4432
[email protected]

Locations (7)

Facility	City	State	ZIP	Site coordinators
University of Colorado \| Anschutz Medical Campus	Aurora	Colorado	80045	Joyce Lee, MD [email protected] 303-724-6109 Olivia Brohl [email protected] 303-724-0640
University of Massachusetts Chan Medical School	Worcester	Massachusetts	01655	Roberto Caricchio, MD [email protected] Betsy Peters, BSN [email protected] 774-455-4432
University of Michigan	Ann Arbor	Michigan	48109	Janelle Pugashetti, MD [email protected] Nisha Mohan [email protected]
Weill Cornell Medicine	New York	New York	10065	Anna Podolanczuk, MD, MS [email protected] 646-962-2333 Alicia Morris, MS [email protected] 646-962-2741
University of Texas Southwestern	Dallas	Texas	75390	Chad Newton, MD [email protected] 214-645-6493 Nighat Sultana, MBBS [email protected] 214-645-6605
University of Virginia	Charlottesville	Virginia	22908	Tessy Paul, MD [email protected] 434-243-2398 Yousef Althulth [email protected]
University of Washington	Seattle	Washington	98195	Ganesh Raghu, MD [email protected] (206) 598-4967 Katherine Palaeologus [email protected] (206)843-0228

Find similar trials in Aurora, CO

By research site

University of Colorado | Anschutz Medical Campus· Aurora, CO University of Massachusetts Chan Medical School· Worcester, MA University of Michigan· Ann Arbor, MI Weill Cornell Medicine· New York, NY University of Texas Southwestern· Dallas, TX University of Virginia· Charlottesville, VA

Related Studies

WTC Chest CT Imaging Archive
Enrolling By Invitation · Icahn School of Medicine at Mount Sinai · New York, New York
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Recruiting · University of Colorado, Denver · Aurora, Colorado
University of Virginia Natural History Study
Enrolling By Invitation · University of Virginia · Charlottesville, Virginia
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
PHASE3 · Enrolling By Invitation · United Therapeutics · Birmingham, Alabama